Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICOLHON
2025-524343-13-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Mar 2026
- Countries
- 1
01
Overview
Phase 2, single-arm trial of Nicobion in Leber hereditary optic neuropathy (LHON), sponsored by Centre Hospitalier Universitaire d'Angers. Planned start Mar 2026; status: authorised.
02
Drugs
Nicobion
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on 2025-524343-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524343-13-00.